About the Myeloid Leukaemia Session
Myeloid leukemia is a type of cancer that affects the blood and bone marrow, where abnormal white blood cells (myeloid cells) multiply uncontrollably. Research in this field focuses on understanding the genetic mutations that drive the development of myeloid leukemia, as well as identifying targeted therapies to treat the disease more effectively. Scientists are also investigating the role of the bone marrow microenvironment in supporting leukemia cell growth and exploring immunotherapies to harness the body's immune system against leukemia cells. Advances in cancer research have led to the development of novel drugs, such as tyrosine kinase inhibitors and monoclonal antibodies, which have shown promising results in clinical trials for patients with myeloid leukemia. However, challenges remain, including drug resistance and the need for more personalized treatment approaches based on the individual's genetic profile.
Topics Covered in Myeloid Leukaemia
Acute & Chronic Forms
Molecular Risk Groups
Bone Marrow Niche
Intensive Induction
Kinase Inhibitors
Measurable Residual Disease
Related Scientific Sessions at CIOC 2027
Why Attend the Myeloid Leukaemia Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Myeloid Leukaemia work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Myeloid Leukaemia research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Myeloid Leukaemia track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Myeloid Leukaemia Conference 2027 — FAQs
What is the Myeloid Leukaemia track at CIOC 2027?
The Myeloid Leukaemia track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Myeloid Leukaemia. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Myeloid Leukaemia sessions?
Cancer researchers and clinicians, educators and students with an interest in Myeloid Leukaemia are all welcome — whether presenting or attending.
Can I present my research in the Myeloid Leukaemia track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Myeloid Leukaemia sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Myeloid Leukaemia track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.